NASDAQ: KRBPKiromic Biopharma Inc Stock
$0.27+0.04 (+17.39%)
Updated Feb 6, 2023
KRBP Price
$0.27
Fair Value Price
$0.26
Market Cap
$4.84M
52 Week Low
$0.15
52 Week High
$1.04
P/E
-0.1x
P/B
17.02x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$38.30M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
44.83
Operating Cash Flow
-$29M
Beta
0.88
Next Earnings
Mar 9, 2023
Ex-Dividend
N/A
Next Dividend
N/A
KRBP Overview
Kiromic BioPharma Incorporated is developing multi-indication allogeneic T cell therapies that exploit the natural potency of the Gamma Delta T cell to target solid tumors. Kiromic BioPharma was founded in 2006 and is headquartered in Houston, TX.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KRBP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KRBP ($0.27) is overvalued by 3.59% relative to our estimate of its Fair Value price of $0.26 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
KRBP ($0.27) is not significantly undervalued (3.59%) relative to our estimate of its Fair Value price of $0.26 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KRBP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KRBP due diligence checks available for Premium users.
Be the first to know about important KRBP news, forecast changes, insider trades & much more!
KRBP News
Valuation
KRBP fair value
Fair Value of KRBP stock based on Discounted Cash Flow (DCF)
Price
$0.27
Fair Value
$0.26
Overvalued by
5.54%
KRBP ($0.27) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KRBP ($0.27) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KRBP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KRBP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.1x
Industry
11.5x
Market
14.99x
KRBP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
17.02x
Industry
5.06x
KRBP is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KRBP's financial health
Profit margin
Revenue
$0.0
Net Income
-$11.9M
Profit Margin
0%
KRBP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$13.0M
Liabilities
$12.7M
Debt to equity
44.83
KRBP's short-term liabilities ($11.11M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KRBP's short-term assets ($2.14M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KRBP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.1M
Investing
$132.4k
Financing
-$114.9k
KRBP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KRBP vs Biotech Stocks
Kiromic Biopharma Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.